In pre-clinical studies, APC-200 has demonstrated the ability to inhibit reactive oxygen species (ROS) formation specifically in prostate cancer cells and thereby blocks inflammation and androgen induced oxidative stress. Whereas acute inflammation is important for host defense, it has been proposed that chronic inflammation contributes to tumor growth, progression to castrate resistant tumors and metastatic progression. In animal studies conducted to date, APC-200 was not only an excellent inhibitor of chronic inflammation, but also significantly delayed prostate cancer progression and increased survival in animal disease models. APC-200 is being developed as an orally administered drug and is in late-stage preclinical development. In 2007, APC-200 received $5 million NCI RAPID Award as a first-in-class therapeutic oral drug for Castrate-Sensitive and Castrate-Resistant Prostate Cancer. Total funding has been approximately $7 million with $1.5 million still remaining to complete the IND data.